» Articles » PMID: 29168263

Incidence and Predictors of Mental Health Disorder Diagnoses Among People Who Inject Drugs in a Canadian Setting

Overview
Specialty Psychiatry
Date 2017 Nov 24
PMID 29168263
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction And Aims: Limited attention has been given to the predictors of mental health diagnoses among people who inject drugs (PWID) in community settings. Therefore, we sought to longitudinally examine the prevalence, incidence and predictors of mental disorder diagnosis among a community-recruited cohort of PWID.

Design And Methods: Data were derived from two prospective cohort studies of PWID (VIDUS and ACCESS) in Vancouver, Canada between December 2005 and May 2015. We used multivariable extended Cox regression to identify factors independently associated with self-reported mental disorder diagnosis during follow-up among those without a history of such diagnoses at baseline.

Results: Among the 923 participants who did not report a mental disorder at baseline, 206 (22.3%) reported a first diagnosis of a mental disorder during follow-up for an incidence density of 4.29 [95% confidence interval (CI) 3.72-4.91] per 100 person-years. In the multivariable analysis, female sex [adjusted hazards ratio (AHR) = 1.74, 95% CI 1.29-2.33], experiencing non-fatal overdose (AHR = 2.33, 95% CI 1.38-3.94), accessing any drug or alcohol treatment (AHR = 1.68, 95% CI 1.24-2.27), accessing any community health or social services (AHR = 1.53, 95% CI 1.02-2.28) and experiencing violence (AHR = 1.60, 95% CI 1.12-2.29) were independently associated with a mental disorder diagnosis at follow-up.

Discussion And Conclusions: We observed a high prevalence and incidence of mental disorders among our community-recruited sample of PWID. The validity and implication of these diagnoses for key substance use and public health outcomes are an urgent priority.

Citing Articles

Early vs. Later Experiences of Violence and Polysubstance Use Among Adults Who Inject Drugs.

Thrasher S, Otachi J, Brune S, Surratt H Subst Use Misuse. 2024; 59(12):1802-1811.

PMID: 39252209 PMC: 11431478. DOI: 10.1080/10826084.2024.2383590.


Gender, homelessness, hospitalization and methamphetamine use fuel depression among people who inject drugs: implications for innovative prevention and care strategies.

Moulis L, Le S, Hai V, Huong D, Minh K, Oanh K Front Psychiatry. 2023; 14:1233844.

PMID: 38025448 PMC: 10661402. DOI: 10.3389/fpsyt.2023.1233844.


Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine.

Machavariani E, Bromberg D, Dumchev K, Dvoriak S, Zeziulin O, Morozova O Contemp Clin Trials. 2023; 131:107248.

PMID: 37263492 PMC: 10527419. DOI: 10.1016/j.cct.2023.107248.


Making community pharmacies psychologically informed environments (PIE): a feasibility study to improve engagement with people using drug services in Scotland.

Matheson C, Hunter C, Schofield J, OSullivan K, Hunter J, Munro A Prim Health Care Res Dev. 2023; 24:e20.

PMID: 36924346 PMC: 10050951. DOI: 10.1017/S1463423623000087.


Association of co-occurring mental health problems with hepatitis C status among young people who inject drugs in rural New Mexico, 2016-2018.

Gupta A, Shebl F, Tong Y, Wagner K, Bassett I, Page K Addict Sci Clin Pract. 2022; 17(1):58.

PMID: 36266666 PMC: 9583516. DOI: 10.1186/s13722-022-00340-3.


References
1.
Mackesy-Amiti M, Donenberg G, Ouellet L . Prevalence of psychiatric disorders among young injection drug users. Drug Alcohol Depend. 2012; 124(1-2):70-8. PMC: 3350828. DOI: 10.1016/j.drugalcdep.2011.12.012. View

2.
Rogler L, Cortes D . Help-seeking pathways: a unifying concept in mental health care. Am J Psychiatry. 1993; 150(4):554-61. DOI: 10.1176/ajp.150.4.554. View

3.
Jane-Llopis E, Matytsina I . Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. Drug Alcohol Rev. 2006; 25(6):515-36. DOI: 10.1080/09595230600944461. View

4.
Pani P, Vacca R, Trogu E, Amato L, Davoli M . Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. Cochrane Database Syst Rev. 2010; (9):CD008373. DOI: 10.1002/14651858.CD008373.pub2. View

5.
Conway K, Compton W, Stinson F, Grant B . Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006; 67(2):247-57. DOI: 10.4088/jcp.v67n0211. View